Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Wolffs (Cardiff, United Kingdom), B. Mansfield (Cardiff, United Kingdom), S. Scofield (Cardiff, United Kingdom), J. Ward (London, United Kingdom), C. Corrigan (London, United Kingdom), Y. Prakash (Rochester, United States of America), P. Kemp (Cardiff, United Kingdom), D. Riccardi (Cardiff, United Kingdom). Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis. 5365

Member's Comments

No comment yet.

Related content which might interest you: Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007 Expression of the MET receptor kinase is a potential functional marker of Idiopathic pulmonary fibrosis Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Transcriptome profiling reveals a potential role for antagonism of the calcium-sensing receptor in the prophylaxis of idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats Source: Eur Respir J 2010; 35: 904-912 Year: 2010 Role of airway smooth muscles in chronic airway inflammation and lung fibrosis and possible therapeutic potential of endothelin receptor antagonism Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010 ?2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis Source: Eur Respir J 2016; 48: 768-779 Year: 2016 Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 The effects of chemokine-like factor1 on murine pulmonary fibrosis Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis Year: 2016 CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease Source: Eur Respir J 2012; 39: 1385-1390 Year: 2012 The cross-talk between TGF-ß and periostin can be targeted for pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019